Evaluation of Inflammatory Markers in LARC Patients
Completed
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- Diagnostic Test: Inflammatory markers
- Registration Number
- NCT05893667
- Lead Sponsor
- Hospital Pedro Hispano
- Brief Summary
Introduction: In locally advanced rectal cancers (LARC), TNM staging is far from optimal. We aimed to investigate the value of previously described circulating biomarkers as predictors of prognosis.
Methods: Retrospective analysis of 245 LARC patients diagnosed between January 2010 and December 2022, who underwent neoadjuvant chemoradiotherapy and surgery at two centers. A Cox regression and Kaplan-Meier analysis were performed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 245
Inclusion Criteria
- patients diagnosed pathologically with rectal adenocarcinomas, located within 12cm from the anal verge (measured by MRI), clinically staged T3-4 and/or N+ and treated with neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery
Exclusion Criteria
- evidence of distant metastasis at diagnosis, emergent or palliative surgery, local excision or "watch and wait" approach and evidence of inflammatory or hematological disorders
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description High levels of inflammatory scores Inflammatory markers - Low levels of inflammatory scores Inflammatory markers -
- Primary Outcome Measures
Name Time Method Overall survival Disease-free survival 5 years
- Secondary Outcome Measures
Name Time Method Pathological response through Ryan Tumor Regression Grade at study completion, average of 5 years TRG 1-5; 1- no viable cancer cells; 5- no fibrosis, with extensive residual disease